GlassScriptPhysician profile
Michelle E Khosla
NPI 1932463551
$6,283.32
in general payments reported to CMS, 2019-2025
26 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $4,274 · 2023: $1,183 · 2024: $307 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,333.45 | 2021-2024 | Intellis Adaptivestim, Synchromedii, Accurian |
| Spinal Simplicity, LLC | $1,795.09 | 2022 | |
| Abbvie INC. | $441.46 | 2022-2025 | |
| Boston Scientific Corporation | $415.98 | 2022-2025 | General - Pain Management, Wavewriter Alpha Prime 16, G4 Rf Generator |
| Collegium Pharmaceutical, INC. | $360.08 | 2022-2024 | Belbuca, Xtampza |
| Abbott Laboratories | $192.62 | 2022 | |
| Vertos Medical, INC. | $190.29 | 2021-2023 | Mild Device Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.32 | 2022-2024 | Relistor |
| Vertex Pharmaceuticals Incorporated | $59.23 | 2025 | |
| Amgen INC. | $44.46 | 2021-2022 | |
| Stryker Corporation | $36.33 | 2023 | Multigen 2 |
| Scilex Pharmaceuticals INC. | $34.99 | 2023-2025 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $23.37 | 2022 | |
| Biodelivery Sciences International, INC. | $23.05 | 2021 | |
| Tersera Therapeutics LLC | $22.56 | 2024 | Prialt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $22.44 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Saluda Medical Americas, INC. | $21.33 | 2024 | Evoke |
| Teva Pharmaceuticals USA, INC. | $16.47 | 2021 | |
| Valinor Pharma, LLC | $16.31 | 2025 | Movantik |
| Indivior INC. | $15.85 | 2024 | Sublocade |
| Hikma Pharmaceuticals USA | $15.68 | 2022 | |
| Painteq LLC | $15.44 | 2024 | Painteq |
| Almatica Pharma LLC | $14.75 | 2021 | |
| Bioventus LLC | $14.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.94 | 2021 | |
| Stimwave Technologies Incorporated | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Khosla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.